KLF15 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | Q9UIH9 |
Other Accession | Q9EPW2, NP_054798.1 |
Reactivity | Human |
Predicted | Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 43992 Da |
Antigen Region | 372-398 aa |
Gene ID | 28999 |
---|---|
Other Names | Krueppel-like factor 15, Kidney-enriched krueppel-like factor, KLF15, KKLF |
Target/Specificity | This KLF15 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 372-398 amino acids from the C-terminal region of human KLF15. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | KLF15 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | KLF15 |
---|---|
Synonyms | KKLF |
Function | Transcriptional regulator that binds to the GA element of the CLCNKA promoter. Binds to the KCNIP2 promoter and regulates KCNIP2 circadian expression in the heart (By similarity). Is a repressor of CCN2 expression, involved in the control of cardiac fibrosis. It is also involved in the control of cardiac hypertrophy acting through the inhibition of MEF2A and GATA4 (By similarity). Involved in podocyte differentiation (By similarity). Inhibits MYOCD activity. Is a negative regulator of TP53 acetylation. Inhibits NF-kappa-B activation through repression of EP300-dependent RELA acetylation. |
Cellular Location | Nucleus |
Tissue Location | Highly expressed in liver, skeletal muscle, and kidney. Expressed in cardiomyocytes. Expression is highly reduced in cardiac tissue of patients with non-ischemic cardiomyopathy and aortic aneurysm, and in glomerular disease. Not expressed in bone marrow or lymphoid tissues. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
KLF15 is a transcriptional activator. Binds to the GA element of the CLCNKA promoter.
References
Yamamoto, K., et al. Biochem. Biophys. Res. Commun. 400(1):175-180(2010)
Haldar, S.M., et al. Sci Transl Med 2 (26), 26RA26 (2010) :
Li, J., et al. BMC Genet. 11, 12 (2010) :
Du, X., et al. J. Clin. Endocrinol. Metab. 94(7):2594-2601(2009)
Wang, B., et al. J. Mol. Cell. Cardiol. 45(2):193-197(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.